Aburaki S, Okuyama S, Hoshi H, Kamachi H, Nishio M, Hasegawa T, Masuyoshi S, Iimura S, Konishi M, Oki T
Bristol-Myers Squibb Research Institute, Bristol-Myers Squibb K. K., Tokyo, Japan.
J Antibiot (Tokyo). 1993 Sep;46(9):1447-57. doi: 10.7164/antibiotics.46.1447.
Synthesis and antifungal activity of pradimicin analogs modified on the aglycone part is described. Upon modification studies at various sites of the aglycone part using pradimicin A (PRM A), C-11 position was found to be the sole site to be modified without loosing antifungal activity. Further modification studies at C-11 position were carried out with 11-OH derivative of pradimicin T1 (PRM T1) because of its easy availability. Among the compounds prepared, 11-demethoxy derivative of PRM A (12) and 11-O-ethyl (13) and 11-O-fluoroethyl (14) derivatives of PRM T1 showed promising antifungal activity comparable to that of PRM A.
描述了在苷元部分进行修饰的普拉地米星类似物的合成及其抗真菌活性。使用普拉地米星A（PRM A）在苷元部分的各个位点进行修饰研究时，发现C-11位是唯一在不丧失抗真菌活性的情况下可进行修饰的位点。由于其易于获得，因此使用普拉地米星T1（PRM T1）的11-OH衍生物在C-11位进行了进一步的修饰研究。在所制备的化合物中，PRM A的11-去甲氧基衍生物（12）以及PRM T1的11-O-乙基（13）和11-O-氟乙基（14）衍生物显示出与PRM A相当的有前景的抗真菌活性。
